Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses

Ringdal, Gerd Inger; Ringdal, Kristen

doi:10.1007/bf00435732

Cited by 193 publications

(97 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…If so, the associations with optimism would have been uniform. This divergence in prediction also attests once again to the importance of distinguishing among the various facets of QOL (Avis et al, 2005;Cella et al, 1993;Osoba et al, 1997;Ringdal and Ringdal, 1993;Schag and Heinrich, 1990;Schag et al, 1991;Schipper et al, 1984).…”

Section: Long-term Cancer Survivorsmentioning

confidence: 93%

“…Deciding how to measure QOL is not as easy as it might seem. After a period when QOL was viewed almost entirely in functional terms, several multiscale inventories were developed to assess QOL after treatment (Borghede and Sullivan, 1996;Cella et al, 1993;Osoba et al, 1997;Ringdal and Ringdal, 1993;Schag et al, 1991;Schag and Heinrich, 1990;Schipper et al, 1984). A key principle behind those measures is that QOL is manifest in diverse ways, all of which may matter.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Quality of life among long‐term survivors of breast cancer: different types of antecedents predict different classes of outcomes

et al. 2005

View full text Add to dashboard Cite

SUMMARYQuality of life (QOL) has many aspects, both in the short-term and in the long-term. Different aspects of QOL may have different types of precursors: demographic, medical, and psychosocial. We examined this possibility in a group of long-term breast cancer survivors. Early-stage breast cancer patients (N ¼ 163) who had provided information about medical, demographic, and psychosocial variables during the year after surgery completed a multidimensional measure of QOL 5-13 years later. Initial chemotherapy and higher stage predicted greater financial problems and greater worry about appearance at follow-up. Being partnered at diagnosis predicted many psychosocial benefits at follow-up. Hispanic women reported greater distress and social avoidance at follow-up. Initial trait optimism predicted diverse aspects of better psychosocial QOL at follow-up, but not other aspects of QOL. Thus, different aspects of QOL at long-term follow-up had different antecedents. Overall, psychological outcomes were predicted by psychosocial variables, presence of a partner at diagnosis, and ethnicity. Financial outcomes, in contrast, were predicted by medical variables, which otherwise predicted little about long-term QOL. This divergence among aspects of QOL should receive closer attention in future work.

show abstract

Section: Long-term Cancer Survivorsmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Quality of life among long‐term survivors of breast cancer: different types of antecedents predict different classes of outcomes

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Two its external validity has been checked in several hundreds hundred and fifty-four patients were randomized to ABMT of patients with lung cancer, 14 and various types of canor second ICC, which were completed in 95 and 104 cer. 15 Its psychometric properties have been also evaluated patients, respectively. Eighteen centers agreed to participate in 125 adults surviving several years after BMT, 16 with a in the QOL study.…”

Section: Methodsmentioning

confidence: 99%

Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial

Zittoun

Suciu

Watson

et al. 1997

Bone Marrow Transplant

114

View full text Add to dashboard Cite

Summary:vary from one study to another, they show generally a lower risk of relapse, and a longer disease-free survival (DFS) after AlloBMT and ABMT than after ICC. A cross-sectional study of quality of life (QOL) was performed in 98 patients in continued first complete From 1986 to 1992, the EORTC and GIMEMA Leukemia Cooperative Groups prospectively compared these remission (CR) for 1-7.4 years, after inclusion in the AML 8A trial which prospectively compared allogeneic three therapeutic options: patients with newly diagnosed AML were entered in the AML 8A trial, and, after the same bone marrow transplantation (AlloBMT), autologous BMT (ABMT) and intensive consolidation chemoinduction and intensive consolidation course, were assigned, according to availability of a family HLAtherapy. Several significant differences between the three treatment groups were observed, on the basis of matched donor or randomization, to AlloBMT, ABMT or a second ICC course. At a median follow-up time of 3.3 patient self-reports, with regard to somatic symptoms (mouth sores, cough, hair loss, headache), repeated years, there was a significantly longer DFS in the AlloBMT (55%) and ABMT (48%) arms than in the ICC arm (30%). 5 acute medical problems, physical functioning, role functioning, leisure activities and, above all, sexual funcHowever, the overall survival after CR was similar in the three arms, patients relapsing after ICC being more easily tioning. There were also significant differences for overall physical condition, and overall quality of life. For all salvaged and frequently receiving an ABMT during second CR. these parameters, the ranking was uniformly AlloBMT lower than ABMT lower than chemotherapy. These dif-The conclusions of this study were based on analyses made according to the intention-to-treat principle. In ferences remain significant after adjustment for time interval between CR and QOL evaluation, sex or age.addition, we have observed a significant difference with regard to the short-term toxicity of the treatment actually These results, confirming a higher risk of permanent impairment of QOL after BMT, may have an impact administered, the treatment-related mortality being 20, 10 and 6% after AlloBMT, ABMT and second ICC, respecton medical decisions and warrant further studies. Keywords: quality of life; acute myeloid leukemia; bone ively. Furthermore, the final results may also be hampered by long-term toxicity, especially due to the conditioning marrow transplantation regimens, with or without total body irradiation (TBI), for both BMT procedures, and to chronic graft-versus-host disease (GVHD) after AlloBMT. Such long-term somatic toxiAllogeneic bone marrow transplantation (AlloBMT), autocity is also likely to induce psychosocial sequelae. Indeed, logous bone marrow transplantation (ABMT), or intensive some previous studies have shown that quality of life consolidation chemotherapy (ICC) are currently proposed (QOL) might be more or less markedly impaired after for patients with acute myelogenous leukemia (AM...

show abstract

“…It is a multidimensional, cancer-specific, and self-administered instrument, 15 cross-culturally tested for reliability and validity. 7,[15][16][17] The instrument consists of 30 items divided into three major domains: functional scales, global health/quality of life (QoL) scale and symptom scales. Functional scales consist of physical (five items), role (two items), emotional (four items), social (two items) and cognitive (two items) items.…”

Section: Data Collectionmentioning

confidence: 99%

A prospective evaluation of patients' health-related quality of life during auto-SCT: a 3-year follow-up

Frödin

Börjeson

Lyth

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

Few studies have evaluated long-term health-related quality of life (HRQL) in patients during auto-SCT. This prospective study examined HRQL in 96 eligible patients before, during and up to 3 years after auto-SCT. The aim of the study was to make a comprehensive assessment of the frequency and severity of different symptoms in patients undergoing auto-SCT. The European Organization for Treatment and Research of Cancer Quality of Life Questionnaire (EORTC QLQ C-30) was administered 13 times. The second week during treatment was the period when patients had the lowest HRQL regarding both total quality of life and function and symptom scales. The patients recovered quickly and just two months after transplantation the baseline values were restored. Three years after transplantation most of the items in the questionnaire had stabilized, except role function and dyspnea, which had improved. There were significant differences between multiple myeloma (MM) and lymphoma patients' physical function, quality of life, fatigue and pain during week 2. At the 3-year follow-up, lymphoma patients indicated a better HRQL than MM patients. The quick recovery of patients after transplantation suggests that treatment is well tolerated; however, the supportive care could be improved at week 2, especially for the lymphoma patients.

show abstract

Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses

Cited by 193 publications

References 21 publications

Quality of life among long‐term survivors of breast cancer: different types of antecedents predict different classes of outcomes

Quality of life among long‐term survivors of breast cancer: different types of antecedents predict different classes of outcomes

Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial

A prospective evaluation of patients' health-related quality of life during auto-SCT: a 3-year follow-up

Contact Info

Product

Resources

About